Monte Rosa Therapeutics, Inc. GLUE Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $159.86M+104% | $129.88M-42.1% | $208.34M+65.9% | $69.43M-36.2% | $78.53M-21.3% | ||
| $4.95M+1.4% | $4.95M+1.9% | $4.95M+0.9% | $4.95M+1.7% | $4.88M+0.3% | ||
| $6.72M+40.0% | $4.48M-12.4% | $5.59M-33.6% | $6.5M+11.1% | $4.8M-13.4% | ||
| $677.55M+104% | $393.19M+4.2% | $401.82M+60.0% | $299.47M+7.8% | $332.28M+66.9% | ||
| $28.41M-3.2% | $25.99M-11.9% | $27.6M-12.2% | $29.05M-12.6% | $29.34M-13.8% | ||
| $24.69M-6.0% | $24.39M-9.1% | $25.07M-8.4% | $25.67M-8.0% | $26.26M-7.6% | ||
| $832K+89.1% | $148K+28.7% | $411K+158% | $445K+113% | $440K+13.1% | ||
| $736.43M+87.3% | $448.66M+2.3% | $459.84M+45.9% | $359.59M+4.5% | $393.2M+47.4% | ||
| $7.9M+21.7% | $3.55M-79.4% | $14.51M+265% | $5.58M-13.8% | $6.49M-5.0% | ||
| $103.64M+515% | $111.33M+589% | $111.89M+346% | $8.06M-76.0% | $16.86M-40.9% | ||
| $4.48M+16.0% | $4.4M+18.4% | $4.24M+16.3% | $4.09M+17.9% | $3.87M+15.5% | ||
| $71.04M+20.0% | $64.21M-59.1% | $61.44M+47.6% | $41.85M-1.2% | $59.22M+43.4% | ||
| $34.58M-9.0% | $34.79M-10.8% | $35.93M-10.3% | $37.04M-9.4% | $38M-9.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $214.51M+81.7% | $215.6M-0.1% | $214M+95.2% | $91.51M-23.4% | $118.04M+3.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $8K+33.3% | $7K+16.7% | $6K0.0% | $6K0.0% | $6K+20.0% | ||
| $1.05B+56.4% | $714.09M+7.4% | $680.16M+3.1% | $675.45M+3.0% | $670.19M+21.2% | ||
| -$521.72M-33.2% | -$477.21M-8.8% | -$431.08M+4.6% | -$404M+5.6% | -$391.7M+1.5% | ||
| -$4.75M-42.6% | -$3.83M-14.0% | -$3.25M-39.8% | -$3.37M-26.3% | -$3.33M-23.6% | ||
| $521.92M+89.7% | $233.06M+4.5% | $245.84M+19.7% | $268.08M+19.3% | $275.16M+80.4% | ||
| $736.43M+87.3% | $448.66M+2.3% | $459.84M+45.9% | $359.59M+4.5% | $393.2M+47.4% | ||
| $0— | $7M— | —— | —— | —— | ||
| $4.61M+227% | $4.6M+2,559% | $4.97M+734% | $2.37M+181% | $1.41M+134% | ||
| $832K+89.1% | $148K+28.7% | $411K+158% | $445K+113% | $440K+13.1% | ||
| $24.69M-6.0% | $24.39M-9.1% | $25.07M-8.4% | $25.67M-8.0% | $26.26M-7.6% | ||
| $24.69M-6.0% | $24.39M-9.1% | $25.07M-8.4% | $25.67M-8.0% | $26.26M-7.6% | ||
| $832K+89.1% | $148K+28.7% | $411K+158% | $445K+113% | $440K+13.1% | ||
| $24.69M-6.0% | $24.39M-9.1% | $25.07M-8.4% | $25.67M-8.0% | $26.26M-7.6% | ||
| $832K+89.1% | $148K+28.7% | $411K+158% | $445K+113% | $440K+13.1% | ||
| $25.59M+57.1% | $26.69M+42.1% | $17.9M+18.6% | $13.77M+7.9% | $16.29M+52.0% | ||
| $33.06M+1.5% | $29.57M-74.8% | $24.79M+31.0% | $18.41M-6.3% | $32.58M+59.6% | ||
| $5.26M+32.8% | $5.27M+42.2% | $4.74M+67.9% | $4.56M+74.4% | $3.96M+54.2% | ||
| $39.06M-6.7% | $39.19M-8.3% | $40.17M-8.1% | $41.13M-7.3% | $41.86M-7.3% | ||
| $1.05B+56.4% | $714.09M+7.4% | $680.16M+3.1% | $675.45M+3.0% | $670.19M+21.2% | ||
| $8K+33.3% | $7K+16.7% | $6K0.0% | $6K0.0% | $6K+20.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $5.26M+32.8% | $5.27M+42.2% | $4.74M+67.9% | $4.56M+74.4% | $3.96M+54.2% | ||
| $4.61M+227% | $4.6M+2,559% | $4.97M+734% | $2.37M+181% | $1.41M+134% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Monte Rosa Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 9.54 — current assets exceed current liabilities.
- Where does Monte Rosa Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.